Literature DB >> 33422492

The epitranscriptome of long noncoding RNAs in metabolic diseases.

Linjie Yin1, Xiao Zhu2, Petr Novák2, Le Zhou2, Ling Gao3, Min Yang1, GuoJun Zhao4, Kai Yin5.   

Abstract

Long noncoding RNAs (lncRNAs) have abundant content and extensive functions that regulate the expression of genes at multiple levels. Recently, transcriptome-wide analysis confirmed that RNA can undergo various chemical modifications in response to stimulation by the environment that further determine the action mechanisms of RNAs and expand the diversity of the transcriptome. Modifications that occur in lncRNAs can affect their expression and the regulation of downstream molecules by changing the secondary structure, splicing, degradation or molecular stability of lncRNAs. During the development of metabolic diseases, reversible RNA modifications show a complex transcriptional landscape. Although a wide quantity and variety of lncRNA modifications have been identified, the knowledge regarding their underlying actions in alcohol use disorders (AUDs), osteoporosis, obesity, and cardiovascular disease (CVD) is still in its infancy. Herein, we will focus on the epitranscriptomic modifications that occur on lncRNAs and the crosstalk between them that affect metabolic diseases.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-methylcytidine (m5C); Epitranscriptomics; Long Noncoding RNA (lncRNA); Metabolic Disease; N6-methyladenosine (m6A); Pseudouridine (ψ)

Mesh:

Substances:

Year:  2021        PMID: 33422492     DOI: 10.1016/j.cca.2021.01.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Epitranscriptomics of cardiovascular diseases (Review).

Authors:  Stefanos Leptidis; Eleni Papakonstantinou; Kalliopi Io Diakou; Katerina Pierouli; Thanasis Mitsis; Konstantina Dragoumani; Flora Bacopoulou; Despina Sanoudou; George P Chrousos; Dimitrios Vlachakis
Journal:  Int J Mol Med       Date:  2021-11-18       Impact factor: 4.101

2.  29 m6A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation - 102 Transcriptomic Dataset Analyses.

Authors:  Ming Liu; Keman Xu; Fatma Saaoud; Ying Shao; Ruijing Zhang; Yifan Lu; Yu Sun; Charles Drummer; Li Li; Sheng Wu; Satya P Kunapuli; Gerard J Criner; Jianxin Sun; Huimin Shan; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  J Immunol Res       Date:  2022-02-15       Impact factor: 4.818

Review 3.  The Regulatory Functions and the Mechanisms of Long Non-Coding RNAs in Cervical Cancer.

Authors:  Qiwei Yang; Ayman Al-Hendy
Journal:  Cells       Date:  2022-03-29       Impact factor: 6.600

4.  DDX59-AS1 is a prognostic biomarker and correlated with immune infiltrates in OSCC.

Authors:  Yang Sun; Qianrong Zhou; Jian Sun; Wei Bi; Ruixue Li; Xingwen Wu; Ni Li; Liang Song; Fei Yang; Youcheng Yu
Journal:  Front Genet       Date:  2022-08-23       Impact factor: 4.772

Review 5.  More than a duologue: In-depth insights into epitranscriptomics and ferroptosis.

Authors:  Justin Chak Ting Cheung; Guangzheng Deng; Nathalie Wong; Yujuan Dong; Simon Siu Man Ng
Journal:  Front Cell Dev Biol       Date:  2022-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.